{"organizations": [], "uuid": "9b91627f59ceb8065cfbb553c81a3f359a91b63a", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180118.html", "section_title": "Archive News &amp; Video for Thursday, 18 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-melinta-therapeutics-says-partner/brief-melinta-therapeutics-says-partner-commenced-new-program-for-topical-formulation-of-radezolid-in-preparation-for-submitting-ind-application-to-fda-idUSFWN1PD0Q6", "country": "US", "domain_rank": 408, "title": "BRIEF-Melinta Therapeutics Says ‍Partner Commenced New Program For Topical Formulation Of Radezolid, In Preparation For Submitting IND Application To FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.412, "site_type": "news", "published": "2018-01-18T20:13:00.000+02:00", "replies_count": 0, "uuid": "9b91627f59ceb8065cfbb553c81a3f359a91b63a"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-melinta-therapeutics-says-partner/brief-melinta-therapeutics-says-partner-commenced-new-program-for-topical-formulation-of-radezolid-in-preparation-for-submitting-ind-application-to-fda-idUSFWN1PD0Q6", "ord_in_thread": 0, "title": "BRIEF-Melinta Therapeutics Says ‍Partner Commenced New Program For Topical Formulation Of Radezolid, In Preparation For Submitting IND Application To FDA", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "fda", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "neutral"}, {"name": "melinta therapeutics, inc.", "sentiment": "neutral"}, {"name": "brief-melinta therapeutics says ‍partner commenced new program for topical formulation of radezolid", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 18 (Reuters) - Melinta Therapeutics, Inc.:\n* MELINTA THERAPEUTICS - ‍PARTNER COMMENCED NEW PROGRAM FOR A TOPICAL FORMULATION OF RADEZOLID, IN PREPARATION FOR SUBMITTING AN IND APPLICATION TO FDA Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-18T20:13:00.000+02:00", "crawled": "2018-01-19T12:18:50.054+02:00", "highlightTitle": ""}